入山 智沙子

Medicine & Life Sciences

1. Cell-Free Nucleic Acids 100%
2. Myelodysplastic Syndromes 89%
3. Lymphoma 84%
4. Fc Receptors 71%
5. Lymphoma, Large B-Cell, Diffuse 67%
6. B-Cell Lymphoma 58%
7. Rituximab 57%
8. Hematologic Neoplasms 56%
9. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 55%
10. Dasatinib 54%
11. Genes 54%
12. 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide 53%
13. 1-phenazinecarboxylic acid 51%
14. Organism Cloning 50%
15. Cancer-Associated Fibroblasts 49%
16. Methylation 47%
17. DNA 47%
18. obinutuzumab 44%
19. Single Nucleotide Polymorphism 44%
20. Complementary DNA 42%
21. Emetine 41%
22. Phosphotransferases 40%
23. Enhancer of Zeste Homolog 2 Protein 40%
24. Radiation Hybrid Mapping 40%
25. Neoplasms 39%
26. Monoclonal Antibodies 38%
27. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 38%
28. Circulating Tumor DNA 38%
29. Leukemia 37%
30. Clonal Evolution 36%
31. Blast Crisis 35%
32. Ionotropic Glutamate Receptors 35%
33. IgG Receptors 35%
34. Clone Cells 33%
35. Granulocyte Colony-Stimulating Factor 33%
36. Hybrid Cells 32%
37. Antibody Specificity 32%
38. Insertional Mutagenesis 31%
39. Mutation 31%
40. Blood Cells 30%
41. Imatinib Mesylate 30%
42. Human Chromosomes 30%
43. Mixed Function Oxygenases 29%
44. 2-hydroxyphenazine 29%
45. Cytotoxic T-Lymphocytes 28%
46. Hematology 28%
47. Pyruvic Acid 28%
48. Gene Library 28%
49. Peripheral Nervous System Diseases 27%
50. Feasibility Studies 27%